162 related articles for article (PubMed ID: 24742019)
1. Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial.
Potthoff K; Habl G; Bruckner T; Suppan C; Hassel J; Jäger D; Indorf M; Debus J
BMC Cancer; 2014 Apr; 14():270. PubMed ID: 24742019
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.
Habl G; Potthoff K; Haefner MF; Abdollahi A; Hassel JC; Boller E; Indorf M; Debus J
BMC Cancer; 2013 Jul; 13():345. PubMed ID: 23855804
[TBL] [Abstract][Full Text] [Related]
3. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.
Argiris A; Bauman JE; Ohr J; Gooding WE; Heron DE; Duvvuri U; Kubicek GJ; Posluszny DM; Vassilakopoulou M; Kim S; Grandis JR; Johnson JT; Gibson MK; Clump DA; Flaherty JT; Chiosea SI; Branstetter B; Ferris RL
Ann Oncol; 2016 Aug; 27(8):1594-600. PubMed ID: 27177865
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT.
Jensen AD; Krauss J; Potthoff K; Desta A; Habl G; Mavtratzas A; Windemuth-Kiesselbach C; Debus J; Münter MW
BMC Cancer; 2011 May; 11():182. PubMed ID: 21595970
[TBL] [Abstract][Full Text] [Related]
6. Skin toxicities associated with epidermal growth factor receptor inhibitors.
Li T; Perez-Soler R
Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
[TBL] [Abstract][Full Text] [Related]
7. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
11. Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients.
Shibata K; Naito T; Hirakawa S; Suzuki K; Hosokawa S; Mineta H; Kawakami J
Cancer Chemother Pharmacol; 2021 Apr; 87(4):555-565. PubMed ID: 33462734
[TBL] [Abstract][Full Text] [Related]
12. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
13. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
14. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Mesía R; Rivera F; Kawecki A; Rottey S; Hitt R; Kienzer H; Cupissol D; De Raucourt D; Benasso M; Koralewski P; Delord JP; Bokemeyer C; Curran D; Gross A; Vermorken JB
Ann Oncol; 2010 Oct; 21(10):1967-1973. PubMed ID: 20335368
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
Frampton JE
Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
[TBL] [Abstract][Full Text] [Related]
16. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
Yokota T
Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
[TBL] [Abstract][Full Text] [Related]
17. A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.
Bahassi el M; Li YQ; Wise-Draper TM; Deng L; Wang J; Darnell CN; Wilson KM; Wells SI; Stambrook PJ; Rixe O
Eur J Cancer; 2013 Jul; 49(10):2345-55. PubMed ID: 23578570
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
Herbst RS; Langer CJ
Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
[TBL] [Abstract][Full Text] [Related]
19. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]